Invent Medic Sweden (IMS) Q3 2024 earnings summary

Executive summary

• Sales and order intake continued to grow steadily, with a significant increase in Efemia Bladder Support sales, up 50% compared to the same quarter last year.

• Successful rights issue post-period strengthened financial position, enabling further investment in product development and market expansion.

• Strategic focus shifted toward NGO partnerships, resulting in stable sales growth and improved cash flow.

• Leadership transition announced: Gunilla Nilsson appointed as new CEO, effective year-end.

Financial highlights

• Q3 2024 net sales: 1,482 KSEK (907 KSEK Q3 2023); YTD net sales: 5,289 KSEK (4,693 KSEK YTD 2023).

• Q3 2024 pre-tax result: -1,602 KSEK (-2,215 KSEK Q3 2023); YTD pre-tax result: -5,194 KSEK (-6,302 KSEK YTD 2023).

• Q3 2024 EPS: -0.04 SEK (-0.06 SEK Q3 2023); YTD EPS: -0.12 SEK (-0.18 SEK YTD 2023).

• Cash and cash equivalents at period end: 1,031 KSEK (954 KSEK Q3 2023).

• Q3 operating expenses: -2,942 KSEK (-3,060 KSEK Q3 2023); YTD: -10,056 KSEK (-10,866 KSEK YTD 2023).

Outlook and guidance

• Proceeds from the rights issue will support sales, marketing, expanded NGO collaboration, and acquisition strategy.

• Focus remains on international expansion, especially in Germany, and continued product portfolio growth.